About Riddhima Chakraborty
Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries.
Recent Articles By Riddhima Chakraborty
1 Software Stock Under $100 to Buy Right Now
Software stock Oracle (ORCL) boasts a lucrative product portfolio and has registered solid top-line growth in its latest quarter. The stock is trading above its 50-day and 200-day moving averages despite the broader market sell-off. Moreover, Wall Street analysts expect it to rally more than 10% in the near term. Also, considering its dividend-paying record, ORCL, which is currently trading under $100, could be an ideal buy now. Keep reading…
1 Pharma Stock to Buy for Under $1 This December
Pharma company Rigel’s (RIGL) REZLIDHIA recently achieved the U.S. Food and Drug Administration’s approval for treating relapsed or refractory acute myeloid leukemia, helping the stock to soar. RIGL shares have gained more than 30% over the past month. Given the industry tailwinds, RIGL might be the ideal stock to buy under $1 this December. Keep reading…
This 1 Stock Can Weather Any Recession
Pfizer (PFE) has been a COVID beneficiary and is expected to continue to gain from its vaccines as the pandemic war is yet to be over. Moreover, PFE offers a more than 3% dividend. Thus, investors might consider buying this quality stock which seems well-positioned to weather any recession. Keep reading…
1 Stock You Shouldn’t Be in Any Hurry to Buy Now
AMC Entertainment (AMC) beat consensus estimates in its 2022 third quarter. However, the stock lost more than 63% in 2022. Also, its bottom line is in the red, and with the looming industry headwinds, it might be a while before AMC reverses its losses. So, the stock could be best avoided now. Keep reading…
1 No-Brainer Stock to Buy When the Market Plunges
CVS Health (CVS) beat revenue and EPS estimates for the 2022 third quarter. Moreover, the stock has gained more than 10% over the past year despite the market turmoil. Also, it currently pays its shareholders a more than 2% dividend. Therefore, CVS might be an ideal buy amid challenging times. Keep reading…
3 Stock Plays to Make Before the End of the Year
The Fed indicated a slowdown in its rate hike pace ahead, boosting investors' optimism. Moreover, the economy is showing resilience in the face of macro headwinds. As December is known to be a strong month for the stock market, investors could load up on fundamentally solid stocks, Microsoft (MSFT), Bristol-Myers Squibb (BMY), and Veritiv (VRTV), before the end of the year. Keep reading…
Want More Passive Income? Give This Dividend King a Try
Honda Motor’s (HMC) current dividend translates to a 7% yield. Moreover, its EPS is expected to rise more than 13% per annum in the next five years. Therefore, investors looking for more passive income amid widespread volatility could consider investing in this dividend king. Keep reading…
1 COVID-19 Stock That's Still a Buy and 1 That's Not
Covid cases continue to get registered to date, and the Biden administration is attempting to allocate more funding to address the pandemic. While investors should consider buying quality COVID-19 stock Pfizer (PFE), we think Teladoc Health (TDOC) might be best avoided now, considering its weak fundamentals. Keep reading…
1 Stock It's Time to Take Short Positions on
Auto stock Nikola (NKLA) beat its revenue estimates for the 2022 third quarter. However, it missed the EPS estimates. Moreover, NKLA reduced its 2022 outlook amid an apparent demand downtrend. The stock has lost more than 75% in 2022 and is trading near its 52-week low of $2.27. So, NKLA might be best avoided or sold short now. Keep reading…